5F-MDMB-PICA

5F-MDMB-PICA (MDMB-5F-PICA^[2]) is a designer drug and synthetic cannabinoid.^{[3][4][5][6][7]} In 2018, it was the fifth-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.^[8]

5F-MDMB-PICA

Clinical data
Other names	5F-MDMB-2201; 5-Fluoro MDMB-PICA
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics)[1] CA: Schedule II DE: Anlage II (Authorized trade only, not prescriptible) UK: Class B US: Schedule I UN: Psychotropic Schedule II
Identifiers
IUPAC name Methyl (2S)-2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate
CAS Number	1971007-88-1
PubChem CID	129597835
ChemSpider	68003951
UNII	NG3U6O970A
KEGG	C22803
Chemical and physical data
Formula	C21H29FN2O3
Molar mass	376.472 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(N[C@H](C(OC)=O)C(C)(C)C)C1=CN(CCCCCF)C2=C1C=CC=C2
InChI InChI=1S/C21H29FN2O3/c1-21(2,3)18(20(26)27-4)23-19(25)16-14-24(13-9-5-8-12-22)17-11-7-6-10-15(16)17/h6-7,10-11,14,18H,5,8-9,12-13H2,1-4H3,(H,23,25)/t18-/m1/s1 Key:CHSUEEBESACQDV-GOSISDBHSA-N

5F-MDMB-PICA is a potent agonist of both the CB₁ receptor and the CB₂ receptor with EC₅₀ values of 0.45 nM and 7.4 nM, respectively.^[9]

In the United States, 5F-MDMB-PICA was temporarily emergency scheduled by the DEA in 2019.^[10] In December 2019, the UNODC announced scheduling recommendations placing 5F-MDMB-PICA into Schedule II.^[11] In the United States 5F-MDMB-PICA was made a permanent Schedule I Controlled Substance nationwide on April 7, 2022.^[12]